Please assess the completion status of the following clinical trial:

Trial Title: Medications Development for Drug Abuse Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion/Exclusion Criteria:~* Participants in this study will be males and females between the ages of 18 and 60 years.~* Applicants must be opioid dependent based upon the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (SCID); in addition, they must have an opioid positive urine during the screening process (or have evidence of opioid withdrawal).~* They must be healthy, with no significant medical illnesses (e.g., insulin dependent diabetes), and without significant psychiatric illness (e.g., schizophrenia) besides their drug dependence.~* Females will have a pregnancy test prior to study enrollment, and if found to be pregnant will be excluded and referred to a substance abuse program for pregnant women (the Center for Addiction and Pregnancy) on the campus.~* Volunteers will also be excluded if they have pre-admission hypotension (due to the use of clonidine in the study).~* Applicants with a history of seizures (including substance-related seizures, such as alcohol withdrawal related) will be excluded.~* Alcohol and/or sedative dependence will be specific exclusionary criteria (given the small risk of seizures associated with tramadol use).~* Allergies to any of the study medications will be grounds for exclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- buprenorphine (Type: ACTIVE_COMPARATOR): Sublingual buprenorphine/naloxone tablets (or placebo)
- clonidine (Type: ACTIVE_COMPARATOR): Oral clonidine tablets (or placebo)
- tramadol ER (Type: EXPERIMENTAL): Oral tramadol tablets (or placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).